Chimeric antigen receptor T-cell therapy-induced nervous system toxicity: a real-world study based on the FDA Adverse Event Reporting System database

Xiayang Ren,Guanmin Zhang,Guohui Li,Yanfeng Wang

DOI: https://doi.org/10.1186/s12885-023-11753-x

IF: 4.638

2024-01-02

BMC Cancer

Abstract:Abstract Background Nervous system toxicity (NST) is one of the most frequent and dangerous side effects of chimeric antigen receptor T-cell (CAR-T) therapy, which is an effective treatment for related tumors in most relapsed/refractory (r/r) hematologic malignancies. Current clinical trial data do not fully reflect the real-world situation. Therefore, this study evaluated the NST of CAR-T therapy using the FDA Adverse Event Reporting System (FAERS). Methods Data were retrieved from FAERS for the period from January 1, 2017 to March 31, 2023. Disproportionality analysis and Bayesian analysis were used for data mining. The reporting odds ratio (ROR) for NST with 95% confidence interval (CI) was calculated for each CAR-T product. The time to onset (TTO) and clinical outcomes due to CAR-T therapy-associated NST were assessed. Results Overall, 6946 cases of NST associated with CAR-T therapy were identified. The patients had a median age of 61 years (interquartile range [IQR]: 47–69 years). Significant signals were observed for all CAR-T products (ROR: 2.19, 95% CI: 2.13–2.44). Anti-CD19 CAR-T products showed a higher NST signal than anti-B cell maturation antigen (BCMA) CAR-T products (ROR 025 2.13 vs. 1.98). Brexucabtagene autoleucel (ROR: 3.17, 95% CI: 2.90–3.47) and axicabtagene ciloleucel (ROR: 2.92, 95% CI: 2.81–3.03) had the two highest NST signals. For the preferred term “brain edema,” the highest signals were obtained for CD28 CAR-T products. The median TTO of NST for all CAR-T products was 7 days (IQR: 3–17 days). The proportion of death, life-threatening and hospitalization adverse events associated with NST was 20.06%, 7.21%, and 32.70%, respectively. The proportion of death outcomes was higher in patients treated with tisagenlecleucel (30.36%) than in those treated with other CAR-T products, except ciltacabtagene autoleucel ( P < 0.001). The proportion of hospitalizations was significantly higher for lisocabtagene maraleucel-associated NST (53.85%) than for other drugs, except for ciltacabtagene autoleucel ( P < 0.001). Conclusions NST is more closely associated with anti-CD19 CAR-Ts and CAR-Ts containing CD28. Serious NST (brain oedema) is likely to occur with CAR-Ts that contain CD28. CAR-T-related NST warrants greater attention owing to the high proportion of serious adverse events and delayed NST.

oncology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to evaluate and compare the relationships between different CAR - T therapies and neurological system toxicity (NST) in the real world, especially their performance in the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database. Specifically, the research aims to:

1. **Evaluate the frequency and severity of neurological system toxicity caused by different CAR - T products**: By analyzing the data in the FAERS database, researchers hope to understand the specific situations of neurological system toxicity caused by different types of CAR - T treatments (such as CAR - T targeting CD19 or BCMA) in practical applications, including the incidence rate, clinical manifestations and severity.

2. **Explore the temporal characteristics of neurological system toxicity**: Researchers have focused on the time from CAR - T treatment to the occurrence of neurological system toxicity (TTO), as well as the development process of these adverse events, in order to better understand the temporal dynamics of this side effect.

3. **Analyze the proportion of neurological system toxicity leading to death, life - threatening situations and hospitalization**: Through statistical analysis, researchers hope to understand the proportion of serious adverse events (such as death, life - threatening situations and the need for hospitalization) caused by different CAR - T products, so as to provide a basis for clinical decision - making.

4. **Explore the associations between specific types of CAR - T products and specific neurological system toxicity**: For example, the study has found that CAR - T products containing the CD28 co - stimulatory domain may be more likely to cause severe neurological system toxicity, especially cerebral edema.

In summary, the main purpose of this paper is to conduct in - depth exploration of the relationship between CAR - T treatment and neurological system toxicity through large - scale real - world data analysis, and to provide a more comprehensive and accurate safety assessment for clinical applications. This will not only help to improve the understanding of the potential risks of CAR - T treatment, but also guide future clinical practice and patient management strategies.